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Background: Ethanol is a cardiotoxic substance that damages the heart by increasing 
apoptosis, free radical formation and calcium overloading.  Consequently, there is an 
increase in cell death leaving fewer functioning myocytes leading to heart failure. 
Sildenafil is a phosphodiesterase type-5 (PDE-5) inhibitor approved for treatment of 
erectile dysfunction. Studies from our lab have demonstrated that PDE-5 inhibition reduces 
myocardial infarct size and attenuates post-ischemic cardiac dysfunction in both ischemia-
ix 
reperfusion and permanent coronary artery ligation models. Therefore, in the present study, 
we hypothesized that treatment with sildenafil will prevent cardiotoxicity associated with 
acute alcohol exposure by reducing myocyte apoptosis and preserving cardiac function 
through PKG signaling. 
Methods and Results: Adult cardiomyocytes were isolated and treated with 100 mM of 
100% ethanol ± 10 µM sildenafil.  At 24 hours necrosis was assessed via trypan blue 
exclusion assay, JC-1 staining assessed mitochondrial membrane potential and ROS 
production was measured by DCF fluorescence.  At 48 hours apoptosis was assessed by 
TUNEL assay.   Ethanol increased the rate of necrotic and apoptotic cell death. This was 
attenuated by co-treatment with sildenafil. Ethanol disrupted the mitochondrial membrane 
potential and increased ROS production. Sildenafil preserved mitochondrial membrane 
potential and attenuated ROS production. Treatment of myocytes with 5-HD, a 
mitochondrial K+atp channel antagonist, blocked the protective effect of sildenafil. 
Knockdown of PKG using adenoviral siRNA blocked the protective effect of sildenafil, 
while overexpression of PKG1α conferred protection against ethanol cytotoxicity. To 
further demonstrate the effect of sildenafil ethanol-cardiotoxicity in vivo, mice were treated 
with ethanol (3 g/kg/day) with or without sildenafil (0.7 mg/kg) by i.p. injection for three 
consecutive days.  After treatment, the animals were sacrificed and the hearts removed and 
perfused on a Langendorff system to measure function. After functional analysis, apoptosis 
and PKG activity was measured in the heart samples. Ethanol decreased the rate-force 
product and increased myocardial apoptosis. Sildenafil preserved cardiac function and 
x 
significantly reduced apoptosis. Sildenafil treated myocardium also showed an increase in 
PKG activity.  
Conclusion: Sildenafil attenuates the toxic effect of ethanol by reducing apoptosis and 
maintaining the mitochondrial integrity in cardiomyocytes.  Sildenafil also preserved 
cardiac function in ethanol-treated mice.  Protein kinase G-dependent signaling plays a 
critical role in attenuating cardiotoxic effect of ethanol.    
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Introduction 
 
The intoxicating effects of alcohol have been known by humanity since ancient 
times.  In fact, the fermentation of sugar into ethanol and the distillation of spirits is one of 
the earliest examples of biotechnology in human history.  In stark contrast to its positive 
hedonic effects, ethanol (CH3-CH2-OH) is a toxic substance. Its chemical structure and 
small size enable it to distribute to every cell of the body.  As a result, alcohol abuse has 
been related to over sixty different disorders and chronic health conditions1.  Alcohol 
abuse is the third leading cause of preventable death.  In the United States, alcohol is 
implicated in the death of more than 100,000 people annually2.  Globally, harmful alcohol 
use is responsible for 2.5 million deaths annually1. 
 
Effect of Alcohol on the Heart 
The effect of alcoholic beverages on the heart and vascular system is complex.  The 
amount consumed, drinking pattern and genetics all influence the health consequences of 
imbibing alcohol-containing beverages.  Despite this complexity, the effect of alcohol on 
cardiovascular risk is consistently depicted as a J-shaped curve.  The consumption of 
alcohol in moderation confers a decreased cardiovascular risk as compared to abstainers. 
Subsequently, people who consume larger amounts of alcohol have increasing 
cardiovascular risk3.  The mechanism by which alcohol-containing beverages lower 
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cardiovascular risk is poorly understood.  This effect is further complicated by the fact that 
the choice of alcoholic beverage also influences cardiovascular risk.  For example, wine is 
more “heart healthy” than distilled spirits or beer.  This is due to the presence of 
cardioprotective compounds found in wine (i.e. resveratrol) 4. Regardless of form, large 
doses of ethanol are toxic to the heart.  They are especially toxic when consumed 
chronically.    
This chronic consumption leads to cardiac damage and cardiac muscle disease, 
called alcoholic cardiomyopathy (ACM).  ACM is a specific form of non-ischemic dilated 
cardiomyopathy5-7.  Unlike viral or autoimmune cardiomyopathies, there is no specific test 
or immunohistochemical marker for ACM and the gross/histological findings are 
indistinguishable from idiopathic dilated cardiomyopathy8. The diagnosis of ACM is a 
presumptive one and should be considered in a patient with cardiac damage, whose history 
is significant for alcohol abuse.  It should be noted that the diagnosis of ACM might be 
considered only after other forms of dilated cardiomyopathy have been ruled out.   
The progression of ACM is initiated by alcohol abuse.  Alcohol abuse damages the 
heart and its ability to pump blood efficiently.  Concurrent to the functional impairment, 
several morphological changes are evident in the damaged heart such as cardiomegaly, 
dilated left ventricle (LV), a normal to reduced cardiac wall thickness, and an increased LV 
mass8.  Under histological analysis, myocardium will display disruptions of myofibrillary 
architecture 9. These morphologic and functional changes mark the asymptomatic phase of 
ACM.  Continued abuse of alcohol leads a progressive and inevitable decline into 
symptomatic cardiomyopathy and heart failure. 
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Ethanol, Acetaldehyde and Cytotoxicity 
A singular pathologic mechanism for the generation of ACM has yet to be clearly 
elucidated.  The task of deciphering such a mechanism is complicated by the fact that 
ethanol and its major metabolite, acetaldehyde, are both cardiotoxic compounds.  When 
ethanol is imbibed, it is passed to the stomach and small intestine where it is rapidly 
absorbed by gastric and intestinal mucosa.  The portal circulation transports ethanol to the 
liver, where it is subjected to first pass metabolism.  The liver is the major site for alcohol 
metabolism, although other organs, including the heart may participate.  Ethanol is 
oxidized by the cytosolic enzyme alcohol dehydrogenase (ADH) to produce acetaldehyde.   
Acetaldehyde is subsequently oxidized by the mitochondrial matrix protein aldehyde 
dehydrogenase to form acetate.  Acetate is then removed from the circulation and excreted 
from the body.   Cardiotoxicity, whether it is directly from ethanol or indirectly by 
acetaldehyde, appears to be mediated by several mechanisms, including apoptosis, 
oxidative stress, contractile protein dysfunction, organelle dysfunction, and neurohormonal 
activation.  
 
Cardiomyocyte Loss 
Cardiomyocyte loss appears to be central to the development of ACM 10.  
Cardiomyocytes may die either by necrosis or apoptosis. Necrosis is commonly seen 
during myocardial infarction and ischemic cardiomyopathy, but is rarely observed in non-
ischemic dilated cardiomyopathy. The myocardium of patients with ACM had disrupted 
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striations and pynknotic nuclei, an observation consistent with apoptosis 11.  More recently, 
hearts from patients with a history of alcoholism displayed a higher apoptotic index, as 
assessed by TUNEL assay.  Also, they displayed altered BAX/BCL-2 ratios, indicating a 
pro-apoptotic state 12.  These studies demonstrated the relationship between long-term 
ethanol consumption and apoptosis in human samples.    
Murine myocardium also displayed an increase in apoptosis and pro-apoptotic 
signaling following ethanol challenge (3g/kg/day i.p. for three consecutive days) 13.  In the 
same study, Ren’s group utilized a novel cardiac-specific over-expression of ADH and 
showed an increase in the rate of apoptosis compared to ethanol alone by “overloading” the 
myocardium with acetaldehyde.   These studies demonstrate that ethanol and acetaldehyde 
damage the myocardium via apoptotic cell death.  
 
Oxidative Stress 
Oxidative stress plays a role in the development of cardiotoxicity leading to ACM.  
The oxidation of ethanol and acetaldehyde leads to free radical production14,15.  The same 
is true for the microsomal ethanol oxidation system (MEOS) as well as the catalase 
pathway for the degradation of ethanol 9.  Glutathione (GSH) is the major, although not the 
only, antioxidant system employed by the cardiomyocyte9,16. GSH exists in the 
cardiomyocyte in either reduced or oxidized state.  In the reduced state, it is able to donate 
a reducing equivalent to reactive molecules such as free radicals.  In doing so, GSH itself 
becomes reactive, only then to interact with another glutathione to form glutathione 
disulfide.  Mice acutely fed ethanol by gavage (5g/kg) demonstrated a decreased cardiac 
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mitochondrial GSH as well as a reduced cytosolic GSH. This was interpreted to be an 
indicator of acute oxidative stress17.  The role of oxidant stress in cardiovascular 
cytotoxicity has been further supported through the use of transgenic mice.  Catalase is a 
peroxisomal enzyme that participates in the oxidation of ethanol.  Catalase couples the 
conversion of H2O2 to H2O, to the oxidation of ethanol.  In light of the role of catalase in 
metabolizing ethanol as well as detoxifying H2O2, it was proposed that by elevating the 
cardiac expression of catalase could shift the cardiomyocyte’s redox state to a more pro-
antioxidant state and prevent oxidative cell damage 18.  Accordingly, it was demonstrated 
that the over-expression of catalase maintained the mechanical function of cardiomyocyte 
in the presence of ethanol through preserved Ca2+ handling and anti-apoptotic cell 
signaling 15,18. 
 The accumulation of reactive oxygen species (ROS) generated by the metabolism 
of ethanol and acetaldehyde, coupled with the depletion of oxidant defenses, creates an 
environment capable of producing cellular damage.  ROS cause damage to cellular 
components such as carbohydrates, proteins, lipids and nucleic acids.   
 
Contractile Protein Dysfunction 
Exposing cardiomyocytes to ethanol in vitro produces a negative inotropic effect.  
This dose-dependent response was subsequently found to be non-linear, suggesting that 
ethanol effects cardiomyocyte contraction in several ways 19.  One possible explanation for 
this observation is that ethanol negatively affects cardiac contractile proteins. It was 
demonstrated that chronic alcohol consumption resulted in a decreased association between 
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actin and myosin in vitro 20. These results suggested that ethanol-induced changes in 
protein function or synthesis might lead to the development of ACM.  Chronic ethanol 
administration reduced the synthesis of myofibrillar and sarcoplasmic proteins 21.  A more 
comprehensive examination of cardiac muscle protein expression revealed myofibrillar, 
sarcoplasmic, membrane-associated as well as mitochondrial proteins were all reduced, 
although the majority of cardiac proteins were not affected by ethanol administration19 
These data support the hypothesis that alcohol may exert its deleterious effect by 
chronically changing the expression patterns of cardiac protein expression, leading to 
contractile defects and eventually overt cardiomyopathy. 
 
Organelle Dysfunction 
Electron microscopy has revealed damage to the intracellular organelles of the 
myocardium of chronically alcohol-dependent patients 22.  In addition to damage and 
disarray of the contractile elements, alcohol caused damage to the mitochondria and the 
sarcoplasmic reticulum.  The mitochondria were increased in number, enlarged, and the 
structure of the mitochondrial cristae also appeared abnormal.  The sarcoplasmic reticulum 
was distended, cystic in appearance and contained increased fatty deposits.    
 An alternate, non-oxidative pathway for the metabolism of ethanol may explain the 
organelle damage observed in the alcoholic heart. Ethanol can be converted to fatty acid 
ethyl esters (FAEEs).  This reaction is catalyzed by FAEE synthase, which has been 
reported to be present in the heart, brain and pancreas23.   When excessive alcohol is 
consumed, FAEEs accumulate in the mitochondria of the heart. This accumulation results 
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in the in the inhibition of both mitochondrial respiration and enzymes of the tricarboxylic 
acid cycle8. Cardiomyocytes rely heavily on mitochondrial respiration for ATP production 
and damage to these processes result in cardiomyocyte death.   
Concomitant to the respiratory defect, there is a disruption in the mitochondria’s 
ability to sequester calcium.  FAEEs will also disrupt the function of the sarcoplasmic 
reticulum.  As FAEEs accumulate, there is a dose-dependent depletion of sarcoplasmic 
reticulum calcium8.  Although direct effects of ethanol on myocardial voltage-gated 
calcium channels cannot be ruled out, the combined defects in mitochondrial and 
sarcoplasmic reticulum calcium handling may underlie the contractile defects seen in 
ACM.    
 
Neurohormonal Activation 
 Ethanol and acetaldehyde have negative effects on the cardiovascular system via 
neurohormonal activation.  While ethanol itself is a cardiac depressant, circulating 
acetaldehyde produces vasoconstriction, positive inotropy and positive chronotropy at 
concentrations < 3 mM9. This effect is mediated through the release of norepinephrine via 
intramural sympathetic nerve fibers innervating the heart8.  Increased levels of circulating 
catecholamines have a well-established role in the progression of heart failure and are 
associated with hypertrophy, apoptosis and LV remodeling8. This point is clearly 
illustrated, as β-antagonist therapy has become a mainstay in the management of heart 
failure.   
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 The ingestion of ethanol activates the renin-angiotensin system (RAS) and is 
associated with the development and potentiation of heart failure.  Cheng et al investigated 
the role of RAS activation in the development of ACM, by blocking the angiotensin II type 
I receptor with irbsartan24.    These investigators demonstrated that chronic alcohol 
administration to dogs resulted in sustained activation of RAS followed by LV dilation and 
dysfunction as well as cardiomyocyte contractile dysfunction.  The co-administration of 
irbsartan blunted RAS activation, prevented pathologic changes to the LV and prevented 
the contractile defect of cardiomyocytes. These data support the hypothesis that hormonal 
activation of RAS contributes to the development of ACM.  The weakness of this study is 
that it fails to establish the causal relationship between RAS activation and LV 
dysfunction.  It is possible that RAS activation is an unfortunate downstream sequelae of 
ethanol ingestion that promotes the progression of asymptomatic ACM to ventricular 
dilation and then failure. 
 
Treatment for Alcoholic Cardiomyopathy 
The foundation for treating ACM has relied on the patient abstaining from alcohol.  
While effective in preventing the progression of ACM, this strategy has proven to be 
difficult.  Clinically, it is difficult, and even dangerous, to convince alcohol-dependent 
subjects to stop drinking as alcoholics exhibit high levels of both physical and 
psychological addiction to ethanol. Furthermore, alcoholics display a high rate of 
recidivism, which leads to progression of disease. Without complete abstinence from 
alcohol, the 4-year mortality rate after developing ACM approaches 50%8. These factors 
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limit the effectiveness of abstinence as a treatment strategy for ACM.  Pharmacologic 
treatment for ACM is also lacking.  Recommendations for treating ACM rely on the 
general guidelines for treating heart failure, and include diuretics, ACE-inhibitors/ARBs, 
β-antagonists, and cardiac glycosides.  Currently, there is no treatment that specifically 
addresses the pathologic mechanisms that underlie ACM, which is cell loss. 
 
 In summary, the mechanism by which ethanol exerts its toxic effect on 
myocardium is poorly understood and complicated by multiple substrates producing 
multiple toxic effects.  The degree to which, apoptosis, oxidative stress, contractile protein 
dysfunction, organelle dysfunction and neurohormonal activation each contribute to the 
development of ACM is not known (Figure 1).  Consequently, the treatment for ACM is 
non-specific and relies on the general guidelines for treating heart failure.  This highlights 
the need for studies that address both the specific pathologic mechanisms that underlie 
cellular toxicity associated with consuming ethanol and disease directed treatments. 
 
Nitric Oxide-Mediated Cell Signaling  
Drugs like nitroglycerine and amyl nitrite have long been known for their powerful 
vasodilatory effect.  Yet, the mechanism by which they worked was not well understood 
until the 1980s when it was discovered that vascular endothelial cells release nitric oxide 
(NO) and it is this gaseous transmitter that functions as a vasodilator.  At that time, the idea 
that a gas, produced by one cell could travel to, cross the cell membrane and influence the 
function of another cell was an entirely novel concept.  In 1998, three scientists won the 
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Nobel Prize for this discovery.  Since that time nitric oxide has been found to participate in 
a number of cellular processes, such as the homeostatic maintenance of blood pressure, the 
penile erection, phagocyte respiratory burst, and neuronal signaling.  
 The cellular signaling involved in the penile erection serves as a prototype for NO-
mediated cell signaling. NO is produced in neurons and vascular endothelial cells by nitric 
oxide synthase (NOS) from the precursor, L-arginine.  Cavernosal smooth muscle cells are 
normally kept contracted under the influence of α-adrenergic stimulation. In response to 
erotic stimuli cavernosal parasympathetic nerves release acetylcholine.  Subsequently, non-
adrenergic, non-cholinergic nerves and vascular endothelial cells release nitric oxide (NO).  
NO rapidly diffuses into smooth muscle cells and activates guanylyl cyclase, converting 
GTP into cGMP.  cGMP accumulation leads to activation of the cGMP-dependent protein 
kinase (PKG).  PKG, a serine/threonine kinase, initiates a signaling cascade that ultimately 
leads to dephosphorylation of the Ca2+/calmodulin-dependent myosin light chain kinase.  
The result is smooth muscle relaxation and vasodilation of the arteries that bring blood to 
the penis.   Compression of the corpus spongiosum restricts the flow of blood out of the 
penis creating a discrepancy between penile inflow and outflow.   Intracavernosal pressure 
rises and results in the penile erection.   
 
NO-mediated Cell Signaling and Neural Protection against Alcohol Toxicity
 Maternal alcohol abuse causes fetal neuron death.  This loss of neurons leads to 
microencephaly and contributes the fetal alcohol syndrome phenotype. NO is present in 
neurons and is produced by neuronal NOS (nNOS).  The absence of nNOS left mice more 
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susceptible to the damaging effects of alcohol in the developing brain25, conversely the 
overexpression of nNOS conferred a neuroprotective phenotype by reducing neuronal 
losses26.  Further investigation revealed that it was the NO-mediated signaling pathway 
that was responsible for protecting neurons against ethanol toxicity25.  In this model, it was 
proposed that the NO-cGMP-PKG signaling pathway conferred neuroprotection against 
ethanol through NF-κB25.  NF-κB is a transcription factor that is normally located in the 
cytosol and is complexed with its inhibitory factor IkappaB.  PKG was demonstrated to 
specifically phosphorylate IkappaB, releasing NF-κB to translocate to the nucleus and 
influence gene transcription27.  The mechanism by which NF-κB confers its protective 
influence is not currently clear, however, it is believed that it alters the regulatory genes of 
the apoptosis pathway. 
 
Phosphodiesterases  
Phosphodiesterases (PDEs) are a class of enzymes that catalyze the hydrolysis of 
one of the ester bonds of cyclic nucleotides.  Thus far, eleven isoforms have been found in 
mammalian tissue28.  Each varies in its tissue distribution as well as its specificity for 
cyclic nucleotide (e.g. cAMP or cGMP).  PDE type 5 is cGMP specific and is highly 
expressed in the corpus cavernosum. It catalyzes the breakdown of cGMP into 5’ GMP, 
depleting the intracellular pool of cGMP and inhibiting NO-mediated cell signaling. 
Sildenafil is a specific PDE5 antagonist. It is structurally similar to cGMP and 
competes for binding at the catalytic site of PDE5.  The inhibition of PDE5 prevents the 
breakdown of cGMP and allows it to more readily accumulate.  The net result is the 
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potentiation of NO-mediated cell signaling and enhanced penile tumescence.  Initial 
studies with sildenafil focused on using it as a treatment for hypertension and angina 
pectoris.  The theory being that PDE5 inhibition would lead to systemic and coronary 
artery dilation.  Unfortunately, this theory did not turn out to be valid. However, many of 
the study volunteers reported fortuitous side effect; improved quality of their erections.  In 
1998, the Pfizer Company released sildenafil under the trade name Viagra™. At that time, 
sildenafil was the first pharmacologic treatment for erectile dysfunction.  Two additional 
agents in this class (tadalafil [CialisTM], vardenafil [LevitraTM]) have also been developed 
and approved by the FDA for treatment of erectile dysfunction. More recently, avanafil 
(Stendra™) has been approved for the same purpose.  Both sildenafil and tadalafil have 
also been approved for treatment of pulmonary hypertension. In recent years, there has 
been tremendous interest in identifying new clinical uses of PDE-5 inhibitors in 
cardiovascular protection29-31. 
 
Sildenafil and Cardioprotection 
Kukreja and colleagues published the first study demonstrating the cardioprotective 
effect of sildenafil in 200232. Sildenafil reduced the infarct size in rabbits following 
ischemia/reperfusion injury. This was abolished by the administration of 5-
hydroxydecanoate (5-HD), a mitochondrial ATP-sensitive potassium channel (mitoK+ATP) 
blocker.  These data suggest that sildenafil confers a preconditioning-like effect at 
clinically relevant doses and that the cardioprotective mechanism is mediated by the 
opening of mitoK+ATP. 
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Subsequent studies revealed that sildenafil treated rat hearts had improved post-
ischemic recovery of function, decreased incidence of ventricular fibrillation and decreased 
area of infarction after being subject to global ischemia in Langendorff mode33. 
Furthermore, 1400W, an iNOS inhibitor, blocked the cardioprotective effect of sildenafil.  
These data demonstrate that the cardioprotective effect of sildenafil is mediated by NO-
dependent signaling. 
It was possible that a hemodynamic effect rather than NO-mediated cell signaling 
could have mediated cardioprotective effect of sildenafil.  To demonstrate this protective 
effect was independent of any vascular response, sildenafil was tested in isolated adult 
mouse cardiomyocytes34.  Simulated ischemia decreased the number of viable myocytes 
with respect to non-ischemic controls.  After eighteen hours of reoxygenation the rate of 
cardiomyocyte apoptosis was increased.  Pretreatment with sildenafil increased cell 
viability and decreased cell loss by apoptosis compared to non-sildenafil treated cells.  
This study demonstrated for the first time that PDE5 was expressed in murine 
cardiomyocytes and that PKG, ERK, iNOS and GSK-3β are involved in the 
cardioprotective mechanism of sildenafil35. 
Sildenafil also has a powerful effect on myocardial infarction induced heart 
failure36. Permanent coronary artery ligation is a more severe ischemic insult and leads to 
the development of post-ischemic remodeling and heart failure.  Sildenafil reduced infarct 
size at 24 hours after permanent coronary artery occlusion.  Treatment with sildenafil 
decreased myocardial apoptosis at day 7 and day 28 and increased the BCL-2/BAX ratio 
indicating an anti-apoptotic effect.  Treatment with sildenafil also improved LV 
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morphology and function, as determined by M-mode transthoracic cardiac 
echocardiography.  Specifically, sildenafil treated hearts had a decreased LV cavity and a 
thicker anterior wall36.  This indicates that less adverse remodeling had occurred with 
sildenafil treated hearts, there was less wall thinning in the infarcted zone and there was 
less chamber dilatation.  Furthermore, sildenafil decreased the rate of aneurysmatic dilation 
of the anterior wall.  Sildenafil preserved cardiac functioning as evidenced by an increase 
in fractional shortening compared to control. 
 
Sildenafil attenuates cardiac hypertrophy 
In 2005, Takimoto et al. demonstrated that chronic administration of sildenafil not 
only prevented, but also reversed cardiac hypertrophy induced by transverse aortic 
constriction37. In this study, the authors showed that sildenafil administration suppressed 
chamber and myocyte hypertrophy, and improved in vivo heart function in mice exposed 
to chronic pressure overload. Sildenafil also reversed pre-established hypertrophy induced 
by pressure load while restoring chamber function to normal.  cGMP catabolism by PDE-
5A increased in pressure-loaded hearts, and therefore inhibition of PDE-5A led to 
restoration of cGMP signaling and activation of cGMP-dependent protein kinase (PKG). 
These studies provided a new potential treatment strategy for cardiac hypertrophy and 
remodeling. 
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Cardiac Protection in Duchenne Muscular Dystrophy  
Duchenne muscular dystrophy (DMD) is a progressive and fatal genetic disorder of 
muscle degeneration.  Patients with DMD lack dystrophin as a result of mutations in the X-
linked dystrophin gene. The loss of dystrophin leads to severe skeletal muscle pathologies 
and cardiomyopathy, a delayed symptom of the disease that usually develops by the 
second decade of life, with more than 90% of patients presenting clinical symptoms by 18 
y of age38. Dystrophin-deficient mice (mdx mice) show cardiac dysfunction with decrease 
in diastolic function followed by systolic dysfunction later in life.  Chronic treatment with 
sildenafil reduced functional deficits in the cardiac performance of aged mdx mice without 
any effect on normal cardiac function in wild type controls 38. When sildenafil treatment 
was started after cardiomyopathy had developed; the established symptoms were rapidly 
reversed within a few days suggesting that PDE5 inhibitors may be a useful treatment 
strategy for cardiomyopathy in DMD patients at early and late stages of the disease. 
 
Sildenafil augments protection following heart transplantation   
Based on the promising cardioprotective effect of sildenafil, Botha et al.  further 
investigated sildenafil-mediated cardioprotection in a rat model of heterotopic cardiac 
transplantation39. Sildenafil citrate (0.7 mg/kg) was administered intravenously to the 
donor 30 min before onset of ischemia or 5 min before reperfusion in the recipient.  The in 
situ cardioplegic arrest was followed by an ischemic time of 3 or 6 hr, transplantation and 
blood reperfusion. In these studies, sildenafil preconditioning but not post-conditioning 
significantly improved initial myocardial systolic and diastolic function after 3 hr of 
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hypothermic cardioplegic arrest. The protective effect of sildenafil declined over a 3-hr 
period of reperfusion along with overall myocardial function, no longer reaching statistical 
significance at 3 hr.  Interestingly, the protective effects of sildenafil were abolished by the 
putative blocker of the mitochondrial ATP sensitive potassium channel, 5-
hydroxydecanoate, before sildenafil administration.  These studies suggest that sildenafil 
pretreatment augments myocardial functional recovery after an ischemic time relevant to 
clinical cardiac transplantation. 
 
Rationale and Specific Aims 
Alcohol abuse has devastating effects on individuals and society, in that it often 
leads to several medical disorders. Thus, it is critical to better understand the effects of 
alcohol ingestion on altered organ function, and develop effective strategies to treat 
alcohol-induced diseases.  As reviewed above, alcohol damages the heart by several 
mechanisms including oxidative stress14,17 and increasing apoptosis12,40,41.  This leads to 
left ventricular dysfunction7 and eventually heart failure9.  Sildenafil and other PDE5 
inhibitors exert powerful cardioprotective effect against ischemia-reperfusion injury 
32,33,36,42-46, heart failure 36, hypertrophy37 and cardiomyocyte necrosis/apoptosis33.  NO 
signaling plays a critical role in cardioprotection 47 as well alcohol-induced neurotoxicity25. 
 
Based on this rationale, we therefore hypothesized that treatment with sildenafil 
would attenuate cardiotoxicity associated with alcohol exposure through mechanisms 
involving cGMP-dependent activation of PKG.  
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Accordingly, the main goals of the present study are:  
 
Aim 1: To demonstrate that PDE-5 inhibition with sildenafil attenuates 
cardiomyocyte death following in vitro exposure of ethanol through activation of 
PKG.  
 
We propose that sildenafil will attenuate cardiomyocyte cell death in vitro following 
exposure to ethanol through PKG activation. We will study the effect of sildenafil on 
ethanol-induced necrosis and apoptosis in cardiomyocytes.  PKG activity will be measured 
in cardiomyocytes following treatment with ethanol and/or sildenafil. Strategies such as 
gene knockdown of PKG Iα or its overexpression in cardiomyocytes would be utilized to 
demonstrate the cause and effect relationship of this enzyme in protection against ethanol 
toxicity.  
 
Aim 2: To show that sildenafil protects against ethanol-induced cardiotoxicity 
through opening of mitochondrial ATP-sensitive potassium channels, preservation of 
mitochondrial integrity and decreased generation of ROS.   
 
We propose that sildenafil-mediated cardioprotection against ethanol toxicity occurs via 
the opening of mitoKatp channels, which is known to stabilize the mitochondrion 48 
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We will show that treatment with sildenafil would preserve mitochondrial membrane 
potential and decrease ROS production in cardiomycytes following exposure to ethanol. 
We will also study the effect of 5-HD, a putative blocker of mitoKATP channels, on 
sildenafil-mediated cardioprotection against ethanol in cardiomyocytes. The mitochondrial 
membrane potential will be measured following ethanol treatment with/without sildenafil 
as well as adenoviral knockdown and overexpression of PKG 1α.  
 
Aim 3: To demonstrate that co-treatment of alcohol with sildenafil attenuates cardiac 
dysfunction and decreases apoptosis in the heart.  
 
We will demonstrate that co-treatment of alcohol with sildenafil attenuates ethanol-induced 
cardiac dysfunction. Using an acute model of alcohol toxicity, we will measure cardiac 
function in the Langendorff isolated perfused heart system.  
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Figure 1.  Mechanisms of Ethanol-Induced Cardiotoxicity.  The development of 
alcoholic cardiomyopathy begins with alcohol abuse.  Ethanol directly, or indirectly 
through acetaldehyde damages the myocardium by creating organelle dysfunction, 
activating renin-angiotensin-aldosterone, altering myocyte protein expression, producing 
oxidative damage or increasing apoptosis.  The end result of each one of these pathways is 
the death and functional loss of cardiomyocytes.  This loss then leads to impaired cardiac 
function. Continued alcohol abuse results in LV chamber dilation and heart failure and is 
called alcoholic cardiomyopathy. 
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Materials and Methods 
 
All animal studies were performed in accordance with the guidelines of the 
National Institutes of Health “Guide for Care and Use of Laboratory Animals”.  The 
Institutional Animal Care and Use Committee of Virginia Commonwealth University 
approved animal experimental protocols.  All animals were housed in a 12:12 hour 
light/dark cycle in a temperature-controlled room.  Animals were fed standard rodent chow 
(Harlan, Indianapolis, ID) and were provided water ad libitum. 
 
Isolation of Primary Adult Rat Cardiomyocytes 
Adult male rats were purchased from Harlan Sprague-Dawley.  Each rat, weighing 
approximately 300 grams, was anesthetized with sodium pentobarbital (100 mg/kg, i.p.).  
Once deep surgical anesthesia was achieved, the thoracic cavity was opened via midline 
sternotomy with Metzenbaum scissors. The superior and inferior vena cava were cut away 
from the heart at the point which they enter the right atrium. The pulmonary vasculature 
was trimmed from the heart in the same manner. The aorta was crosscut at a point distal to 
the coronary arteries but proximal to the brachiocephalic artery. The heart was removed 
from the chest; the aorta was quickly cannulated and attached to a Langendorff perfusion 
apparatus. The aorta was secured to the perfusion apparatus with a single suture tied 
circumferentially around the vessel.  Care was taken to not obstruct coronary flow.  The 
aorta was retrogradely perfused (37° C) at a constant pressure of 55 mmHg for about 5 
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minutes with Ca2+-free bicarbonate-based buffer containing (in mM): 120 NaCl, 5.4 KCl, 
1.2 MgSO4, 1.2 NaH2PO4, 5.6 glucose, 20 NaHCO3, 10 2,3-butanedione monoxime, and 5 
taurine, which was continuously bubbled with 95% O2 and 5% CO2. Collagenase type II 
(Worthington, 0.5 mg/mL) and protease type XIV (0.02 mg/mL) was added to the 
bicarbonate buffer. The enzymatic digestion proceeded for 15 minutes.  50 µM Ca2+
 
was 
then added in to the enzyme solution and the heart was perfused for another 10-15 minutes.  
The digested ventricular tissue was cut away from the atria and aorta.  It was then cut into 
chunks and placed into an Eppendorf tube containing the bicarbonate buffer.  The 
myocytes were mechanically dissociated by repeated gentle aspiration into a transfer 
pipette.  The cellular material was then passed through a 100 µm nylon cell strainer (BD 
Bioscience) and centrifuged. The cell pellet was re-suspended in a three-step calcium 
restoration procedure (i.e. 125, 250, 500 µM Ca2+).  The freshly isolated cells were 
suspended in Medium 199, containing 2 mM l-carnitine, 5 mM creatine, 5 mM taurine, 5 
M glucose, 0.1 µM insulin, and 1% penicillin-streptomycin. The cells were plated on cell 
culture dishes, which were pre-coated with 20 µg/mL mouse laminin in PBS for 1 hour. 
The cardiomyocytes were cultured in the presence of 5% CO2 for 1 hour in a humidified 
incubator at 37° C, which allowed cardiomyocytes to adhere to the dish surface prior to the 
experimental protocol.  
 
In vitro treatment Protocol 
Myocyte cultures were randomly assigned into treatment groups (Figure 2).  In 
experiments using adenoviral genetic manipulations, adenoviral infection preceded 
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ethanol/sildenafil treatment by 1 hour.  Absolute ethanol (100%) was dissolved directly 
into the medium to yield a final ethanol concentration of 100 mM.  Stock solution of 
sildenafil (obtained from Pfizer Inc) was prepared by dissolving the powder into sterile 
H2O.  This was further diluted into cell culture medium to yield a final concentration of 10 
µM.  This concentration was chosen because it conferred robust protection against necrosis 
and apoptosis in isolated cardiomyocytes following simulated ischemia/reoxygenation as 
reported previously 33.  5-HD was co-administered at 50 nM dissolved in media. 
 
Knockdown of PKG1α with adenoviral shRNA  
In order to knock down the expression of PKG1α we used siRNA targeting the 
mouse cDNA of PKG Type I (GenBank accession number NM_001013833).  This 
corresponded to bases 1593 to 1611 and targeted the sequence 5’-
GAACAAAGGCCATGACATT-3’ (Dhammacon Research Inc., Lafayette, CO).  A non-
targeting scrambled RNA duplex siRNA control (NTSC, Dharmacon) containing 21-
nucleotide sequences demonstrating no homology to murine genes was also used as a 
control for transfection. Transient transfections of duplex siRNAs (100 nm) were 
performed in H9C2 cells using siPORT™ amine (Ambion).  After 48 h, RNA was isolated 
by Tri-Reagent (Molecular Research Center), and RT-PCR and quantitative real-time PCR 
were performed. After confirming the significant reduction of PKG expression in H9C2 
cells using this duplex siRNA targeting the mouse PKGI, shRNA expression vector for 
PKG was constructed using the pSilencer™ adeno1.0-CMV system from Ambion 
(Adenoviral siRNA expression Vector System). The hairpin siRNA oligonucleotide (55-
23 
mer) sequence 5′-
TCGAGGAACAAAGGCCATGACATTttcaagagaAATGTCATGGCCTTTGTTCAGA-3′ 
(mouse PKGI with sequence in capital letters and loop in lowercase italics) and its 
antisense with XhoI and SpeI were synthesized, annealed, and subcloned into the pSilencer 
adeno 1.0-CMV shuttle vector. HEK293 cells were transfected with linearized shRNA 
vector together with adenoviral LacZ backbone to generate a recombinant adenovirus.as 
described by Das et al 2008.  Cells were infected with the virus at a concentration of 1 x 
103 particles/cell. 
 
Overexpression of PKG Iα  
The adenoviral vector for overexpression of PKG Iα was constructed by cloning 
the human PKG Iα as described 34.  Cardiomyocytes were infected with adenoviral vector 
containing PKG Iα of the catalytically inactive PKG IαK390A.  Cells were infected with 
the virus at a concentration of 1 x 103 particles/cell. 
 
Assessment of Cardiomyocyte Necrosis:   
Necrosis was assessed by trypan blue exclusion assay. Cardiomyocytes were 
treated for 24 hours. At the end of the treatment protocol, 20 µl of 0.4% Trypan Blue 
(Sigma-Aldrich) was added into the culture dish.  After 5 min of equilibration, the cells 
were counted under a Nikon inverted microscope using a 10X objective.  Three 
representative fields were chosen at random from each sample and then averaged.  
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Necrosis was expressed as the percentage of trypan positive cells over the total number of 
cells in each field of view.  
 
Assessment of Cardiomyocyte Apoptosis   
Cardiomyocyte apoptosis was assessed by terminal dUTP nick-end labeling 
(TUNEL) using the ApoAlert™ DNA Fragmentation Assay (BD Bioscience, Palo Alto, 
CA).  Following the experimental protocol, cardiomyocytes were fixed in 4% formalin 
dissolved in phosphate-buffered saline.  TUNEL assay was then performed according to 
manufacturer’s instructions.   Following fixation, the cells were washed in a Coplin jar 
containing room temperature PBS for five minutes.  The cells were then permeabilized by 
immersing them in pre-chilled 0.2% Triton X-100 in PBS for five minutes on ice. The cells 
were again rinsed in PBS. Excess PBS was removed and the cells were covered in 
equilibration buffer for 10 minutes.  The equilibration buffer was then removed and 50 µl 
TdT incubation buffer was placed on the cells.  The tailing reaction was carried out in a 
dark, humidified, 37° C for sixty minutes.  Equilibration buffer was used in place of the 
TdT reagent for a negative control.  DNAase-I was applied for a positive control.  The 
tailing reaction of terminated by immersing the slides in a Coplin jar containing 2X SSC 
and incubated in room temperature for fifteen minutes. Following the TUNEL assay the 
slides were cover-slipped in Vectashield containing 4′, 6-diamidino-2-phenylindole 
(DAPI) in order to visualize cell nuclei.  The cardiomyocytes were examined on a Nikon 
epifluorescent inverted microscope under a 10X objective.   A FITC filter was used to 
detect apoptotic cardiomyocyte nuclei.  Apoptotic cells exhibit strong nuclear green 
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fluorescence.    An ultraviolet filter was used to detected DAPI-stained cardiomyocyte 
nuclei. Three representative fields were chosen at random from each sample and averaged. 
Cardiomyocyte apoptosis was expressed as a function of TUNEL positive nuclei over total 
cells per field.  
 
Assessment of Cardiomyocyte PKG Activity 
Cardiomyocyte PKG activity was measured with a CycLex cGMP-dependent 
Protein Kinase Assay Kit (MLI International, Woburn MA).  This PKG activity assay uses 
a peroxidase coupled anti-phospho-G-kinase substrate threonine 68/119 monoclonal 
antibody as a reporter.  The colorimetric assay is performed in an ELISA format.  
Cardiomyocytes were isolated, plated on 100x20 mm cell culture dishes and treated in 
triplicate.  Following the treatment protocol, the cardiomyocytes were scraped off of the 
culture dish with a cell scraper and collected with the culture media into a 15 ml tube.  The 
samples were spun down and rinsed three times in phosphate-buffered saline.   The cell 
pellet was then placed in ice-cold lysis buffer (Cell Signaling) and homogenized.  The 
homogenate was centrifuged at 10,000 g for 10 minutes at 4° C.  The supernatant was be 
recovered as the total cellular protein.  100 µl of sample was transferred into a 96-well 
plate provided in the kit and allowed to incubate for 30 minutes at 30 ° C.  The wells of the 
96-well plate were pre-coated recombinant PKG substrate.  The wells were then washed 
and then 100 µl of horseradish peroxidase conjugated anti-phospho-specific antibody was 
added and allowed to incubate for 1 hour at room temperature. The wells were washed and 
100 µl of substrate reagent was added.  Absorbance was then measured at 450 nm.  
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Absorbance was expressed in arbitrary units per µg of cell protein.  Total protein 
concentration was determined by Bradford assay. 
 
Assessment of Cardiomyocyte Mitochondrial Membrane Potential (∆Ψm) 
Mitochondrial membrane potential was assessed using 5,5’, 6,6’-tetrachloro-1, 1’, 
33’- tetraethylbenzimidazole-carbocyanide iodine (JC-1, Biocarta, San Diego, CA).  After 
24 hour experimental incubation period, cells were incubated with 2 µg/ml JC-1 for 10 
minutes at 37°C.  The cells were washed in phosphate-buffered saline and examined under 
a Nikon epifluorescent inverted microscope with a 10X objective.  A dual-wave emission 
filter was used to simultaneously record emission from both green and red emission 
wavelengths.  Red fluorescence represented the potential-dependent aggregation of JC-1 in 
the mitochondria. Green fluorescence represents the monomeric form of the dye remaining 
in the cytosol. The ratio of aggregate verses monomeric forms of JC-1 were counted. 
Cardiomyocytes were counted from three representative fields per sample and averaged.  
Mitochondrial membrane potential was expressed as a ratio of mitochondrial aggregate 
(red emission) to the monomeric (green emission) form of JC-1. 
 
Acute Model of Ethanol Toxicity 
Adult male CD-1 mice, weighing approximately 30 grams were purchased from 
Harlan.  The acute model of ethanol toxicity used in this study was previously described13.  
In brief, ethanol (3 g/kg/day) was administered by intraperitoneal (i.p.) injection for three 
consecutive days (Figure 3).  This dose was divided into two equal volumes and was 
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administered once in the morning and then again in the evening.  Mice were randomized 
into one of four groups.  Group 1 received saline only and served as a control.  Group 2 
received ethanol treatment (3.0 g/kg/day i.p.).  Group 3 received sildenafil (0.7 mg/kg i.p.).  
Group 4 received both ethanol (3.0 g/kg/day i.p.) and sildenafil (0.7 mg/kg i.p.). This dose 
of sildenafil was chosen because it simulates a 70 kg male taking a 100 mg tablet of 
sildenafil with 49% bioavailability of PO administration (100 mg / 70 kg) x 49% = 0.70 
mg/kg). Each group received the same volume of intraperitoneal injection each day.   
 
Assessment of Cardiac Function  
Following three treatment days, mice were anesthetized with sodium pentobarbital 
(100 mg/kg).  Once deep surgical anesthesia was achieved, the thoracic cavity was opened 
via midline sternotomy with Metzenbaum scissors. The superior and inferior vena cava 
were cut away from the right atrium and the pulmonary vasculature was cut away from the 
heart in the same manner. The aorta was cross cut at a point distal to the coronary arteries 
but proximal to the brachiocephalic artery. The heart was removed from the chest and 
placed into a small dish containing ice-cold Krebs-Henseleit buffer.  The aorta was quickly 
cannulated and mounted onto a Langendorff perfusion system. The aorta was secured to 
the perfusion apparatus with a single suture tied circumferentially around the vessel.  Care 
was taken to not obstruct coronary flow. The aorta was retrogradely perfused (37° C) at a 
constant pressure of 55 mmHg with Krebs-Henseleit buffer containing (in mM): NaCl 118, 
NaHCO3 24, CaCl2, 2.5, KCl 4.7, KH2PO4 1.2, MgSO4 1.2, Glucose 11, EDTA 0.5. The 
perfusion solution was continuously gassed with 95% O2 + 5% CO2 and warmed by a 
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warming bath. The heart temperature was continuously monitored and maintained at 37 °C 
throughout the experiment.  After the heart began to spontaneously contract, a force-
displacement transducer (Grass, Model FT03) was attached to the cardiac apex with a No. 
5 surgical thread and a metal hook. The resting tension of the isolated heart was adjusted to 
0.30 grams. Ventricular developed force was recorded with a Beckman R-5llA polygraph 
connected to the force transducer.  Prior to each experiment the force transducer was 
calibrated.  The heart was allowed to stabilize for 30 minutes, at which point cardiac 
functional parameters were recorded.  Rate force product, an index of myocardial oxygen 
demand and workload, was calculated by multiplying developed force with the heart rate.  
Coronary flow rate was measured by timed collecting the coronary artery effluent for one 
minute.  Following functional analysis the hearts were placed in 10% formalin or snap-
frozen in liquid nitrogen. 
 
Assessment of Myocardial Apoptosis 
Following functional analysis and fixation in 10% formalin, the heart was rinsed 
and PBS.  The tissue was dehydrated and embedded in paraffin.  The tissue was sectioned 
in the transverse plane in 5 µm sections and placed on a glass microscope slide.  The tissue 
was de-parafinized in xylene bath and re-hydrated.   TUNEL assay was then performed 
according to manufacturer’s instructions. The heart sections were then permeabilized by 
immersing them in pre-chilled 0.2% Triton X-100 in PBS for five minutes on ice. The 
sections were rinsed in PBS. Excess PBS was removed and the sections were covered in 
equilibration buffer for 10 minutes.  This was followed by incubation with 50 µl TdT 
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buffer. The tailing reaction was carried out in the dark at 37° C for 60 minutes. For a 
negative control equilibration buffer was used in place of the TdT reagent and for a 
positive control DNAase-I was applied.  The tailing reaction was terminated by immersing 
the slides in a Coplin jar containing 2X SSC and incubated in room temperature for fifteen 
minutes. Following the TUNEL assay the slides were cover-slipped in Vectashield 
containing 4′, 6-diamidino-2-phenylindole (DAPI) in order to visualize cell nuclei.  The 
myocardial sections were examined on a Nikon epifluorescent microscope under a 10X 
objective.   A FITC filter was used to detect apoptotic cardiomyocyte nuclei.  Apoptotic 
cells exhibit strong nuclear green fluorescence.    An ultraviolet filter was used to detected 
DAPI-stained myocardial nuclei. Three representative fields were chosen at random from 
each sample and averaged. Myocardial apoptosis was expressed as an apoptotic index (AI).  
In this system one is not clearly able to differentiate one myocardial cell from another and 
cardiac cells are multinucleate.  Therefore AI is a function of TUNEL positive nuclei over 
total nuclei cells per field. 
 
Assessment of Myocardial PKG Activity 
Myocardial PKG activity was measured with a CycLex cGMP-dependent Protein 
Kinase Assay Kit (MLI International, Woburn MA).  This PKG activity assay uses a 
peroxidase coupled anti-phospho-G-kinase substrate threonine 68/119 monoclonal 
antibody as a reporter.  The colormetric assay is performed in an ELISA format.  Whole 
hearts were snap-frozen in liquid nitrogen.  Frozen hearts were then crushed in a clean 
mortar and pestle with liquid nitrogen.  The myocardial powder was then placed in ice-cold 
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lysis buffer (Cell Signaling) and homogenized on ice.  The homogenate was centrifuged at 
10,000 g for 10 minutes at 4° C.  The supernatant was recovered as the total cellular 
protein.  100 µl of sample was transferred into a 96-well plate provided in the kit and 
allowed to incubate for 30 minutes at 30 ° C.  The wells of the 96-well plate were pre-
coated recombinant PKG substrate.  The wells were then washed and then 100 µl of horse 
radish peroxidase conjugated anti-phospho-specific antibody was added and allowed to 
incubate for 1 hour at room temperature. The wells were washed and 100 µl of substrate 
reagent was added.  Absorbance was then measured at 450 nm.  Absorbance was expressed 
in arbitrary units per µg of cell protein.  Total protein concentration was determined by 
Bradford assay. 
 
Statistics 
Data was expressed mean ± standard error of the mean.  Difference between groups 
was analyzed with a one-way ANOVA with a Bonferroni post-hoc.  P < 0.05 was 
considered statistically significant. 
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Figure 2.  In Vitro Model of Ethanol-induced Cardiomyocyte Toxicity.   Adult rat 
cardiomyocytes were isolated by enzymatic digestion with collagenase and plated in 
calcium-free bicarbonate buffer.  This technique yields a culture of approximately 95% 
rod-shaped myocytes.  These cells were then subjected to experimental procedures to 
include adenoviral gene manipulation, ethanol treatment and/or sildenafil treatment.  At 24 
hours of treatment trypan blue exclusion assay, JC-1 fluorescence, DCF fluorescence, and 
PKG activity were measured.  At 48 hours TUNEL assay was performed. 
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Figure 3. Acute Model of Ethanol-induced Cardiotoxicity.  Mice were given ethanol 1.5 
g/kg twice daily by intraperitoneal injection for three consecutive days (3.0 g/kg/day).  
Sildenafil was given to certain groups at a dose of 0.7 mg/kg also by intraperitoneal 
injection.  On the fourth day the animals were sacrificed and cardiac function was 
measured in Langendorff mode. In addition, apoptosis was measured by TUNEL assay and 
PKG activity was measured using CycLex cGMP-dependent Protein Kinase Assay Kit . 
 
 
 
 
 
 
 
33 
 
 
Results 
 
 
The effect of sildenafil on cardiomyocyte cell death 
 
Central to the development of ACM appears to be cardiomyocyte loss 10.  
Cardiomyocytes may die either by necrosis or apoptosis. Necrosis is commonly seen 
during myocardial infarction and ischemic cardiomyopathy, but is rarely observed in non-
ischemic dilated cardiomyopathy.  In the present study, we tested the hypothesis that PDE-
5 inhibition with sildenafil attenuates cardiomyocyte death through activation of PKG in 
an in vitro model of ethanol toxicity.  To accomplish this aim, primary adult rat 
cardiomyocytes were isolated and then treated with 100 mM ethanol ± 10 µM sildenafil for 
24 hours.  Necrosis was assessed by Trypan Blue exclusion assay and apoptosis was 
assessed by TUNEL as described in the Methods. Treatment of cardiomyocytes with 
ethanol for 24 hours increased the rate of necrotic cell death compared to control (Figure 
4).  Co-treatment with 10 µM sildenafil attenuated ethanol-induced increased cell death (P 
< 0.001 vs. ethanol alone).  Sildenafil alone had no significant effect on cardiomyocyte 
necrosis compared to control. Furthermore, ethanol treated cardiomyocytes displayed an 
increased apoptotic rate compared to control (Figure 5, P < 0.01).  Co-treatment with 
sildenafil attenuated the ethanol-induced cardiomyocyte apoptosis (P < 0.01 vs. ethanol 
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alone). There was no significant effect of sildenafil on cardiomyocyte apoptosis when 
compared to the control untreated group (P > 0.05). 
 
Protein Kinase G activity 
 
Protein Kinase G (PKG) or cGMP-dependent protein kinase is a serine/threonine 
specific protein kinase that is one of the major intracellular receptors for cGMP. This 
serine/threonine protein kinase has two isozymes (type I and type II; i.e. PKGI and PKGII) 
that are presented in eukaryotic cells. The N terminus of PKGI is encoded by two 
alternatively spliced exons that produce the isoforms, α and β49-51.  PKGIα is mainly found 
in lung, heart, platelets, and cerebellum, whereas PKGIβ is highly expressed with PKGIα 
in smooth muscles of uterus, vessels, intestine, and trachea 52,53.  More importantly, the 
activation of PKG phosphorylates numerous intracellular proteins that in turn regulate 
many important physiological functions such as control of vascular tone, cell 
differentiation and proliferation, and platelet aggregation 52. Previous studies from this lab 
have demonstrated that sildenafil has a potent cardioprotective effect against 
ischemia/reperfusion injury 32,36,44-46.  To determine whether the protective effect of 
sildenafil against necrosis and apoptosis occurs through a PKG-dependent mechanism, we 
measured PKG activity in cardiomyocytes exposed to ethanol in presence and absence of 
sildenafil. The results show that exposure of cardiomyocytes to 10 µM sildenafil increased 
the activity of PKG compared to control myocytes (Figure 6, P < 0.05).  The presence of 
ethanol did not significantly effect PKG activation by sildenafil when compared to 
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sildenafil treated cardiomyocytes.  Ethanol treatment consistently displayed a trend toward 
increasing PKG activity, but it was not statistically significant from control. 
 
Effect of PKG Iα knockdown on Sildenafil-mediated protection against ethanol 
toxicity 
Previous studies have shown that pharmacological inhibitors of PKG blocked 
preconditioning of cardiomyocytes 54,55.  Moreover, the PKG inhibitors KT 5823, 
guanosine 3’,5’ cyclic monophosphorothioate, 8-(4-chloro-phenylthio)  and DT-2 blocked 
the anti-necrotic and anti-apoptotic effect of sildenafil 34.  Knockdown of PKG with siRNA 
has also been shown to abolish the cardioprotective effect of sildenafil against ischemia 
reperfusion injury.  In order to demonstrate the cause and effect of PKG activation in 
sildenafil-induced protection against ethanol toxicity, siRNA was used to knock down 
PKG 1α.  Cardiomyocytes were infected with adenovirus containing either scrambled 
siRNA (shControl) or siRNA directed against PKG Iα (shPKG). Adenoviral infection with 
shControl or shPKG had no effect on cardiomyocyte necrosis or apoptosis (Figures 7 and 
8, respectively).   shControl + Sildenafil + Ethanol demonstrated cardioprotection and was 
not significantly different from shControl + Sildenafil with respect to necrotic and 
apoptotic cell death.  Knockdown of PKG blocked the cardioprotective effect of sildenafil 
against ethanol toxicity.  This was evident by an increase rate of necrosis (P < 0.01 vs. 
shPKG + Sildenafil) and apoptosis (P < 0.001 vs. shPKG + Sildenafil). 
 
Effect of PKG Iα overexpression on ethanol-mediated necrosis and apoptosis 
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Previous studies from the laboratory have shown that overexpression of PKG Iα, 
even in the absence of any preconditioning stimulus, conferred a cardioprotective effect 34.  
In these studies, adult rat cardiomyocytes were infected with adenoviral vectors containing 
PKGIα or catalytically inactive mutant PKGIαK390A prior to simulated ischemia and 
reoxygenation.  PKGIα overexpression resulted in significant decrease in necrosis and 
apoptosis following simulated ischemia and reoxygenation34. To examine the effect of 
PKG Iα in attenuation of ethanol-induced cardiotoxicity, adult rat cardiomyocytes were 
infected with adenovirus to overexpress PKG Iα.  Over-expression of PKG1α reduced 
ethanol-induced necrosis (Figure 9, P < 0.01) and apoptosis (Figure 10, P < 0.05) as 
compared to the cardiomyocytes infected with the catalytically inactive mutant 
PKGIαK390A inactive mutant.  Adenoviral infection and overexpression of PKG Iα had 
no significant effect on cardiomyocyte necrosis or apoptosis (Figure 9 and 10, 
respectively). 
 
Assessment of Mitochondrial Membrane Potential (∆Ψm) 
In the present study, we used the cationic lipophilic probe JC-1 to assess the 
mitochondrial membrane potential (ΔΨm) 56-58.  The mitochondria of non-apoptotic cells 
appear in red following the aggregation of the JC-1 reagent, which emits red fluorescence 
at 590 nm. In contrast, in the apoptotic or dead cells the JC-1 dye remained in its 
monomeric form, thereby emitting relatively more green fluorescence JC-1 exhibits a 
potential dependent accumulation in the mitochondria and as such exhibits red 
37 
fluorescence at approximately 590 nm.  When mitochondria are depolarized there is a shift 
in the fluorescence to green at approximately 529 nm.  Exposure of adult rat 
cardiomyocytes to 100 mM ethanol for 24 hours resulted in dissipation ∆Ψm as illustrated 
by JC-1 immunofluorescence (Figure 11, P < 0.001 vs. control).  Cardiomyocytes that 
were co-treated with 10 µM sildenafil and ethanol preserved the mitochondrial membrane 
potential (P < 0.001 vs. ethanol alone).  Sildenafil alone had no significant effect on ∆Ψm 
compared to control. Knockdown of PKG with siRNA blocked sildenafil-mediated 
preservation of ∆Ψm (Figure 12, P < 0.0), while overexpression of PKG1α preserved ∆Ψm 
(Figure 13).  Adenoviral control and mutant PKG had no effect on ∆Ψm. 
 
Role of mitochondrial ATP-sensitive K+ channel in Protection against Ethanol 
Toxicity with Sildenafil 
 
Opening of the mitochondrial ATP-sensitive K+ (mitoKATP) channel plays an 
important role in ischemic as well as pharmacological preconditioning with sildenafil in 
the heart32,59. Opening the mitoKATP channel partially compensates the membrane 
potential, which enables additional protons to be pumped out to form a H+ electrochemical 
gradient for both ATP synthesis and Ca2+ transport60.  Opening of this channel allows the 
cardiomyocyte to regulate intracellular calcium levels as well as cell swelling.  This 
preserves mitochondrial functioning and prevents initiation of apoptosis.  Sarcolemmal 
channels are the premier sensors of the energy state of the myocyte and, when activated, 
shorten or interrupt the action potential 61. 5-Hydroxydedecanoate (5-HD) is a putative 
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blocker of mitochondrial mitoKATP channel which has been shown to block the protective 
effect of ischemic preconditioning in the heart 62. To determine if sildenafil protects 
cardiomyocytes against ethanol toxicity through opening of  mitoKATP channel, adult rat 
cardiomyocytes were treated with ethanol in the presence of 5-HD.  This group displayed a 
higher rate of necrosis compared to ethanol alone (Figure 14, P < 0.001).  When co-treated 
with ethanol, sildenafil and 5-HD, an increased rate of necrosis was observed as compared 
to ethanol and sildenafil (P < 0.001).  5-HD blocked sildenafil-mediated preservation of the 
mitochondrial membrane potential in the presence of ethanol as well (Figure 15, P < 0.01).   
This loss of mitochondrial membrane potential was not statistically different from ethanol 
and 5-HD (P > 0.05). 
 
Assessment of ROS production 
As reviewed in the above text, oxidative stress plays a role in the development of 
cardiotoxicity leading to ACM.  The oxidation of both ethanol and acetaldehyde lead to 
free radical production  (35, 47).    The accumulation of ROS generated by the metabolism 
of ethanol and acetaldehyde, coupled with the depletion of oxidant defenses, creates an 
environment capable of producing cellular damage.  In the present study, we investigated 
the role of sildenafil in attenuation of ROS generation in cardiomyocytes following 
exposure to ethanol.  The adult rat cardiomyocytes were incubated with ethanol in the 
presence and absence of ethanol.    ROS production was measured by DCF fluorescence as 
described in the Methods.  Figure 16 shows that ethanol treatment caused significant 
increase in ROS production, which is clearly indicated by enhanced intensity of DCF 
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fluorescence (P < 0.001 vs. control).  Co-treatment with sildenafil and ethanol attenuated 
the ethanol-induced ROS production.  Sildenafil alone had no effect on ROS production as 
compared with control. 
 
Ethanol and Cardiac Dysfunction  
 
To further demonstrate the effect of sildenafil in protecting against ethanol 
cardiotoxicity in vivo, we treated adult male CD-1 mice with ethanol (3 g/kg) ± sildenafil 
(0.7 mg/kg) by i.p. injection for three consecutive days.  On the fourth day, the animals 
were sacrificed, the hearts isolated and perfused in Langendorff mode and cardiac function 
was measured.  Coronary flow rate was determined by a timed collection of the coronary 
artery effluent. Ethanol decreased the rate force product (Figure 17A, P < 0.01 vs. control). 
Co-treatment with sildenafil attenuated cardiac dysfunction  (P < 0.01 vs. ethanol alone).  
Sildenafil alone had no effect on the rate force product compared to control.  Furthermore, 
co-administration of 5-HD displayed decrease the rate force product as compared to 
ethanol and sildenafil treated group (P < 0.01 vs. ethanol + sildenafil).  There was no 
significant difference in heart rates between any groups (Figure 17 B), nor was there any 
difference in coronary flow rates (Figure 17 C).   
 
 
 
Myocardial Apoptosis 
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Acute ethanol toxicity has been shown to increase myocardial apoptosis 13. Such a 
loss of cells represents an early phase of the progression of alcoholic cardiomyopathy.  
Thus, preventing cell loss during initial stages of ethanol toxicity would represent 
significant advancement in prevention alcohol-related cardiac disease.    Accordingly, we 
hypothesized that sildenafil will decrease the rate of myocardial apoptosis in response to 
acute ethanol toxicity.   Our results show that ethanol administration in mice caused 
myocardial apoptosis as indicated by the increase in TUNEL positive nuclei (Figure 18, P 
< 0.001 vs. control).  The administration of sildenafil attenuated the ethanol-induced 
increase in the myocardial apoptotic index (P < 0.001 vs. ethanol alone).  Sildenafil alone 
had no significant effect on myocardial apoptosis compared to control. 
 
Myocardial PKG Activity 
  Sildenafil administration increased myocardial PKG activity in both sildenafil and 
sildenafil + ethanol groups (Figure 19, P < 0.01 vs. control).  The administration of ethanol 
did not affect PKG activity in ethanol alone compared to control or ethanol + sildenafil 
compared to sildenafil alone. 
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Figure 4. Representative images of cardiomyocytes and quantitative data showing the 
effect of sildenafil pretreatment on ethanol-induced toxicity. A. Color photomicrograph 
with a 10x objective. Cardiomyocytes stained with trypan blue.  Blue staining is indicative 
of loss of cell membrane integrity and thus necrotic cell death. Note that the number of 
trypan blue positive cells were significantly reduced in sildenafil+ethanol-treated myocytes 
as compared to ethanol alone. B. Quantitative results of anti-necrotic protection of 
sildenafil against ethanol toxicity 
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A.
    
B. 
 
Figure 5. Effect of sildenafil on inhibition of apoptosis in cardiomyocytes following 
exposure to ethanol.  A.  TUNEL assay images showing green punctate dots indicative of 
fragmented nuclei associated with apoptosis. A significant number of cardiomyocytes 
underwent apoptosis (i.e. TUNEL-positive) with EtOH exposure whereas sildenafil 
pretreatment reduced TUNEL-positive nuclei (EtOH+sil).  B. Ethanol increased the rate of 
cardiomyocyte apoptosis.  Sildenafil decreased the ethanol-induced increase in apoptosis. 
Control EtOH EtOH + Sil Sil 
10x Objective Arrows indicate Tunel Positive Nuclei 
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Figure 6.  PKG Activity in Cardiomyocytes.  Treatment with sildenafil increased PKG 
activity.  Ethanol administration did not significantly affect PKG activation. 
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Figure 7. Effect of PKG1α silencing (knockdown) on anti-necrotic effects of sildenafil 
against ethanol toxicity in adult rat cardiomyocytes.  Adenoviral knockdown of PKG Iα 
increased the number of trypan blue positive cardiomyocytes treated with sildenafil and 
ethanol (sPKG+SIL+EtOH) as compared to the corresponding control virus infected cells 
(shControl+SIL+EtOH). There was no significant difference in the number of trypan blue 
positive cells between the shControl+SIL and shPKG+SIL treated groups.  As expected, 
EtOH significantly increased number of trypan blue positive cells as compared to non-
treated control cardiomyocytes. 
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Figure 8. Effect of PKG1α silencing (knockdown) on anti-apoptotic effects of 
sildenafil against ethanol toxicity in adult rat cardiomyocytes.  Adenoviral knockdown 
of PKG Iα increased the number of TUNEL positive cardiomyocytes treated with sildenafil 
and ethanol (sPKG+SIL+EtOH) as compared to the corresponding control virus infected 
cells (shControl+SIL+EtOH). There was no significant difference in the number of 
TUNEL positive cells between the shControl+SIL and shPKG+SIL treated groups.  As 
expected, EtOH significantly increased number of TUNEL positive cells as compared to 
non-treated control cardiomyocytes.   
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Figure 9. PKG1α inhibits ethanol-induced necrosis in adult rat cardiomyocytes.  
Adenoviral overexpression of PKG Iα reduced the number of trypan blue positive necrotic 
cardiomyocytes following treatment with ethanol (adPKG1α+EtOH) as compared to the 
ethanol (EtOH) and overexpression of corresponding catalytically inactive PKGIαK390A 
(adMut+EtOH) groups.  There was no significant difference in the number of trypan blue 
positive cells between the control, adPKG1α and adMut groups 
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Figure 10. PKG1α inhibits ethanol-induced apoptosis in adult rat cardiomyocytes.  
Adenoviral overexpression of PKG Iα reduced the number of TUNEL positive 
cardiomyocytes following treatment with  ethanol (adPKG1α+EtOH) as compared to the 
ethanol (EtOH) and overexpression of corresponding catalytically inactive PKGIαK390A 
(adMut+EtOH) groups.  There was no significant difference in the number of TUNEL 
positive cells between the control, adPKG1α and adMut groups.    
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Figure 11. Effect of sildenafil on preservation of mitochondrial membrane potential 
(∆Ψm) in cardiomyocytes. A. Color micrograph with a 10x objective. JC-1 fluorescence. 
Isolated rat cardiomyocytes were loaded with cationic lipophilic probe JC-1. Note the 
predominant aggregate (nonapoptotic) mitochondria (in red/orange color) in control, 
ethanol+sildenafil (EtOH+Sil) and sildenafil alone (Sil) as compared to the ethanol alone 
(EtOH) treated group which shows green fluorescence indicating the monomeric form of 
JC-1 and a disruption of mitochondrial membrane potential. B. Quantification of JC-1 
aggregate/monomer ratio, which shows sildenafil (Sil) increased significantly the ratio (i.e. 
lesser lost in ΔΨm) as compared with the untreated ethanol group. No significant 
difference in the ΔΨm was observed between the control, EtOH+Sil and Sil groups.  
 
 
 
 
 
 
Control EtOH EtOH + Sil Sil 
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Figure 12. Role of PKG1α on sildenafil-induced preservation of mitochondrial 
membrane potential (∆Ψm) following ethanol exposure of cardiomyocytes.   Isolated 
rat cardiomyocytes were loaded with cationic lipophilic probe JC-1.  Note the green 
fluorescence indicating the monomeric form of JC-1 and a disruption of  ∆Ψm in the 
ethanol (EtOH) and sildenafil plus ethanol  treatment in cardiomyocytes with adenoviral 
knockdown of PKG Iα (shPKG+Sil+EtOH) as compared with the predominant aggregate 
(nonapoptotic) mitochondria (in red/orange color) in control, control adenovirus infected 
cells (shControl), PKG1α silencing (knockdown) adenovirus (shPKG), control adenovirus 
with sildenafil (shContol+Sil), control adenovirus with sildenafil and ethanol 
(shContol+Sil+EtOH) treated groups.   B. Quantification of JC-1 aggregate/monomer ratio, 
which shows the same trend of ∆Ψm as in stated in A.
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Figure 13. Direct effect of PKG1α in sildenafil-induced preservation of mitochondrial 
membrane potential (∆Ψm) in cardiomyocytes following exposure to ethanol.     
Adenoviral overexpression of PKG Iα preserved ∆Ψm cardiomyocytes following treatment 
with  ethanol (adPKG1α+EtOH) as compared to the ethanol (EtOH) and overexpression of 
corresponding catalytically inactive PKGIαK390A (adMut+EtOH) groups.  There was no 
significant difference in the ∆Ψm between the control, adPKG1α and adMut groups.  
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Figure 14.  Role of MitoKATP channels in Sildenafil-induced protection against 
Cardiomyocyte toxicity. Note that the number of trypan blue positive cells are 
significantly with 5-hydroxydecanoate (5-HD) following treatment with ethanol + 
sildenafil (EtOH+Sil+5-HD) as compared with ethanol+sildenafil-treated myocytes.  It is 
also noteworthy that trypan blue positive cells were significantly higher following 
treatment with ethanol + as compared to ethanol alone suggesting pro-necrotic effect of 5-
HD.  
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Figure 15.  Effect of 5-hydroxydecanoate (5-HD) on loss of mitochondrial membrane 
potential (∆Ψm) following treatment with sildenafil and ethanol in cardiomyocytes.  
on preservation of in cardiomyocytes.    Note that co-treatment of ethanol (Et-OH), 
sildenafil (Sil) and 5-HD caused loss of ∆Ψm as compared to the untreated control, 
ethanol+sildenafil (EtOH+Sil) and sildenafil (Sil) treated groups.  5-HD alone also caused 
significant loss of ∆Ψm.  The ∆Ψm between ethanol (EtOH), ethanol+5-HD (EtOH+5-HD) 
and ethanol+sildenafil+5HD (EtOH+Sil+5-HD) treated groups was not significantly 
different.    
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Figure 16. Sildenafil inhibits reactive oxygen species (ROS) generation following 
ethanol treatment in cardiomyocytes.  Note that ethanol treatment causes an increase in 
cardiomyocyte ROS production as indicated by increase in DCF fluorescence.    Treatment 
with sildenafil blunted ethanol-induced increase in ROS (EtOH+Sil).     
54 
 
 
 
A.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
55 
 
 
 
C. 
 
  
 
 
 
 
 
Figure 17. Sildenafil preserves cardiac function via opening of mitoKATP channels in 
ethanol treated mice. A. Rate force product.  Note that treatment with ethanol (3.0 
g.kg/day) decreased the rate-force product as compared to the control mice.  Co-treatment 
with sildenafil (0.7 mg/kg) preserved cardiac function (EtOH+Sil).  5-HD blocked the 
sildenafil-induced preservation of function. B. Heart rate.  There was no significant 
difference between the groups. C.  Coronary Flow.  No significant difference in the 
coronary flow rate was observed between the groups.  
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Figure 18.  Effect of sildenafil on inhibition of apoptosis in the heart following 
following treatment with ethanol.  A.  TUNEL assay images.  White arrows indicate 
apoptotic nuclei indicative of fragmented nuclei associated with apoptosis. A significant 
number of cardiomyocytes underwent apoptosis (i.e. TUNEL-positive) with EtOH 
treatment whereas sildenafil pretreatment reduced TUNEL-positive nuclei (EtOH+sil).  B. 
Bar diagram showing quantitative data on apoptosis.   Ethanol increased the rate of 
myocardial apoptosis.  Co-treatment with sildenafil attenuated the ethanol-induced 
increased in myocardial apoptosis. 
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Figure 19. PKG activity in heart. Treatment with sildenafil increased PKG activity.  
Ethanol administration did not significantly affect PKG activation. 
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Discussion 
 
Excessive chronic alcohol ingestion causes both histopathologic and functional 
changes in multiple organs, especially in the liver, heart, and pancreas, and can result in 
serious or even fatal illness. Chronic, excessive alcohol consumption has been reported to 
be the most frequent identifiable cause of heart muscle disease 63 and has been shown to 
decrease the contractility of heart muscle in both animals and humans 64.  Its classical 
clinical cardiac consequence is a dilated cardiomyopathy, which can lead to congestive 
heart failure and even to death.  There exist no unique identifying features that set 
alcoholic cardiomyopathy apart from other causes of heart failure. The diagnosis is further 
complicated by the frequent presence of other risk factors for cardiomyopathy. History is 
key, as is a definite lack of other inciting factors, such as certain prescribed or non-
prescribed drugs (e.g. doxorubicin, cocaine) or ischemic heart disease, to strengthening the 
diagnosis, which remains one of exclusion. When clinically manifest, alcoholic 
cardiomyopathy demonstrates 4-chamber dilation, low cardiac output, and normal or 
decreased left ventricular wall thickness. Clinical stigmata of heart failure, such as a third 
heart sound, elevated jugular venous pulse, and cardiomegaly with or without rales, may 
be seen, especially in decompensated states. The coexistence of liver disease due to 
cirrhosis may give rise to diagnostic confusion when the picture may be less 
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straightforward. The association of supraventricular arrhythmias with heavy alcohol intake 
(holiday heart syndrome) and an association with sudden cardiac death are further 
complications of alcohol abuse in alcoholic cardiomyopathy patients 65,66.  Based on the 
observations of Fauchier et al 67, the causes of death in patients with alcoholic 
cardiomyopathy are similar to those with idiopathic cardiomyopathy: progressive chronic 
heart failure and sudden cardiac death.   Moreover, alcoholics with simultaneous 
cardiomyopathy and cirrhosis carry a worse prognosis68. 
 Many cellular and molecular mechanisms of injury have been proposed as the 
basis for alcoholic cardiomyopathy, including apoptosis 12, mitochondrial dysfunction 13, 
acetaldehyde protein adduct formation 69 and oxidant stress 70.  
 
Medical therapy available for alcoholic cardiomyopathy is no different from that 
for other etiologies of heart failure, except it should include abstinence from alcohol as a 
cornerstone 71,72.  Survival is poor in those who continue to drink heavily, with 4-year 
mortality levels close to 50%.  One should follow the heart failure guidelines, such as those 
adopted by the European Society of Cardiology or the American College of 
Cardiology/American Heart Association referred to earlier, that incorporate the use of 
certain beta-blockers and ACE inhibitors or angiotensin receptor blockers (ARBs). 
Diuretics and digitalis can be used in the management of symptomatic alcoholic 
cardiomyopathy patients. Some of these patients may have coexisting nutritional 
deficiencies (vitamins, minerals such as selenium or zinc), which may need correction as 
well, because they can independently worsen outcomes or hamper attempts at treatment.  
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Sildenafil is a selective potent inhibitor of PDE5 (a cGMP-specific isoform of 
PDE), which promotes increase in cGMP in vascular smooth muscle cells by preventing its 
breakdown with PDE5 73.  In the present study, we investigated the potential role of 
sildenafil in attenuating the alcohol-induced cardiotoxic effect in cardiomyocytes and 
intact heart.  This approach was based on strong rationale provided by several basic 
science studies demonstrating the cardioprotective effect of sildenafil and other PDE-5 
inhibitors in a number of clinical scenarios including ischemia/reperfusion injury, 
myocardial infarction, heart transplantation, cardiac hypertrophy, heart failure, 
doxorubicin-induced cardiotoxicity, Duchenne muscular dystrophy and stem cell 
preconditioning 29,30,43.  Our results show that treatment of adult cardiomyocytes with with 
100 mM ethanol increased the rate of necrotic cell death compared to control (Figure 4).  
Co-treatment with sildenafil attenuated ethanol-induced increased cell death.    
Furthermore, ethanol treated cardiomyocytes displayed an increased apoptotic rate 
compared to the control (Figure 5) and co-treatment with sildenafil attenuated the ethanol-
induced cardiomyocyte apoptosis as well.    Moreover, we demonstrated that the protective 
effect of sildenafil against ethanol cardiotoxicity was attributed to the PKG-dependent 
signaling, preservation of mitochondrial membrane potential, opening of mitochondrial 
ATP-sensitive K+channels and decreased generation of ROS.  Furthermore, our results 
showed that sildenafil co-treatment with ethanol preserved cardiac function in the isolated 
perfused heart and inhibited apoptosis as compared to ethanol treated mice.   Taken 
together, these results provide strong evidence that sildenafil has protective effect against 
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ethanol-induced toxicity in adult cardiomyocytes in vitro and preservation of cardiac 
function in the intact heart.  Moreover, these results on sildenafil-induced anti-apoptotic 
effect may have potential therapeutic ramification in the treatment of alcohol-induced 
cardiomyopathy. 
   
Like many other cardiovascular diseases such as atherosclerosis, myocardial 
ischemia and reperfusion injury, and diabetic cardiomyopathy, apoptosis plays a pivotal 
role in the pathogenesis of alcoholic cardiomyopathy 74.  The up-regulated expression of 
caspase-3 and Bax, as well as increased TUNEL positive cells and caspase-3 activity 
depicted the presence of a global myocardial apoptosis following chronic ethanol intake 75.  
Moreover, ethanol intake was found to promote phosphorylation of JNK and ASK-1, two 
pivotal pro-apoptotic signaling molecules.   Over time, apoptosis leads to structural 
changes that are maladaptive and will eventually lead to heart failure.   The present study 
demonstrated significant in increase in necrosis as well as apoptosis following acute 
treatment with ethanol, which was significantly attenuated by co-treatment with sildenafil 
and ethanol.  Also, sildenafil decreased ethanol-induced apoptosis in the intact heart.  
These data further support previous results showing inhibition of necrosis and apoptosis by 
sildenafil in murine cardiomyocytes subjected to simulated ischemia and reoxygenation, 
attenuation of apoptosis following doxorubicin and ischemic cardiomyopathy through 
upregulation of Bcl2/Bax ratio and inhibition of caspase-336,76.  It is notable that the 
protective dose of sildenafil used in the present study was 10 µM (∼6.9 µg/ml), which is in 
the physiological range of its therapy in patients. 
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PDE-5 is the major enzyme that is responsible for catalytic break-down of cGMP in 
the vascular smooth muscle cells 77, its inhibition leads to increased cGMP accumulation 
and subsequent activation of PKG.  Therefore, we evaluated the role of PKG in sildenafil-
induced protection against alcohol toxicity.  We used two complimentary approaches to 
accomplish this goal:  (a) siRNA directed against PKG Iα (shPKG) to knock down PKG 
1α, which is mainly found in lung, heart, platelets, and cerebellum; (b) adenoviral vectors 
containing PKGIα to overexpress this protein in cardiomyocytes.   Cardiomyocytes were 
infected with adenovirus containing either scrambled siRNA (shControl) or siRNA 
directed against PKG Iα (shPKG).  Knockdown of PKG blocked the cardioprotective effect 
of sildenafil against ethanol toxicity.  This was evident by an increase rate of necrosis and 
apoptosis (Figure 7 & 8).  Furthermore, PKGIα overexpression (in the absence of 
sildenafil) also resulted in significant decrease in necrosis and apoptosis in cardiomyocytes 
treated with ethanol as compared to the cardiomyocytes infected with the catalytically 
inactive mutant PKGIαK390A (Figures 9 & 10). These highly complementary approaches 
conclusively demonstrate that PKG is mediator of the protective effect of sildenafil against 
alcohol-induced toxicity in cardiomyocytes.    
 
It is well known that apoptosis is a cellular process involving a genetically programmed 
series of events leading to the death of a cell.    During this process, several key events 
occur in mitochondria including the release of caspase activators including cytochrome c, 
changes in electron transport and loss of mitochondrial membrane potential (∆Ψm) which 
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is coupled to the generation of ATP by the F1/F0 subunits of ATP synthase 78.  A 
dissipated mitochondrial membrane potential causes activation of the mitochondrial 
permeability transition pore (MPTP) with the subsequent release of cytochrome c and the 
initiation of apoptosis.   For this reason, measurement of ∆Ψm is an important parameter of 
mitochondrial function (in terms of ATP production) and has been used as an indicator of 
cell death.  Exposure of adult rat cardiomyocytes to ethanol caused significant dissipation 
∆Ψm as illustrated by JC-1 immunofluorescence (Figure 11).     Sildenafil significantly 
preserved the mitochondrial membrane potential (P < 0.001 vs. ethanol alone).   
Interestingly, knockdown of PKG with siRNA blocked sildenafil-mediated preservation of 
∆Ψm (Figure 12), while overexpression of PKG1α preserved ∆Ψm (Figure 13).  These 
results provide first direct evidence on the role of PKG in preservation of ∆Ψm following 
ethanol treatment in cardiomyocytes.  The signaling mechanism by which PKG leads to 
preservation of ∆Ψm following ethanol treatment is not clear.   Previous investigation form 
the laboratory identified a novel PKG-dependent cytoprotective mechanism of sildenafil 
against ischemia/reperfusion injury involving phosphorylation of ERK, and GSK3β, and 
induction of Bcl-2 34.  GSK3β is the phosphorylation target of phosphatidylinositol 3-
kinase/Akt 79. Activation of GSK3β has been shown to induce myocardial apoptosis 80 by 
Akt 81. Hypoxic preconditioning, which also activates PKC, was shown to phosphorylate 
and inhibit GSK3β and cause protection in adult cardiomyocytes, through its ability to 
modulate mitochondrial permeability transition, a key component of mitochondria-
mediated cardiac cell death following ischemia-reperfusion 82.  Moreover, PKGIα 
overexpression in cardiomyocytes enhanced phosphorylation of Akt, ERK1/2, and JNK, 
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increased Bcl-2, inducible nitric-oxide synthase, endothelial nitric-oxide synthase, and 
decreased Bax expression. Interestingly, 5-HD and glibenclamide (the KATP channel 
blockers) abolished PKGIα-mediated protection against necrosis and apoptosis 83. 
Another interesting observation in the present study is the role of mitochondrial 
KATP channels in protection against ethanol toxicity in cardiomyocytes and the intact heart. 
When co-treated with ethanol, sildenafil and 5-HD, an increased rate of necrosis was 
observed as compared to ethanol and sildenafil.  5-HD blocked sildenafil-mediated 
preservation of ∆Ψm in the presence of ethanol as well (Figure 15).  Moreover, sildenafil 
induced preservation of cardiac function following treatment of mice with ethanol was 
blunted by 5-HD (Figure 17).    During an energy crisis, such as ischemia, mitoKATP 
channels may open and in doing so, an inward rectifying current is created.  This current 
allows for the maintenance of the mitochondrial membrane potential and buffers the 
mitochondria against accumulating calcium and prevents cellular swelling.  
Pharmacological agents that open mitoKATP provide a strong preconditioning-like signal to 
cardiac myocytes and enable them to survive ischemic insult.  Garlid et al. first proposed 
that mitoKATP channels were involved in the cardioprotective effect 84. By using 
reconstituted mitochondrial vesicles or isolated mitochondria and measuring potassium 
flux, these investigators demonstrated that heart and liver mitoKATP channels shared 
pharmacological properties with the channels found in sarcolemma while possessing a 
distinct profile. Furthermore, it was shown that opening of mitoKATP channels leads to the 
generation of reactive oxygen species (ROS) by the mitochondria and represents an 
important mechanism that is required for the cardioprotective effect of IPC 85,86. Opening 
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of these channels allowed potassium to enter the mitochondrial inner matrix, which causes 
generation and release of ROS from the respiratory chain 87.  ROS then act as second 
messengers to activate a downstream pathway of protective kinases, including protein 
kinase C (PKC), that finally converge on the cardioprotective end effector.   Studies from 
our laboratory have shown that sildenafil induces a preconditioning-like stimulus and 
promote cardiomyocytes survival via opening of mitoKATP channels 33.  Whether such a 
pathway of ROS acting as second messengers to activate a downstream pathway of 
protective kinases, such as PKC is operative in sildenafil-induced protection against 
alcohol toxicity needs investigations in the future.  
In the present study, ethanol treatment caused significant increase in ROS 
production, which is clearly indicated by enhanced intensity of DCF fluorescence (Figure 
16, P < 0.001 vs. control).  Co-treatment with sildenafil and ethanol attenuated ethanol-
induced ROS production while sildenafil alone had no effect on ROS production as 
compared with control.  Excessive ethanol intake is known to trigger oxidative stress and 
apoptosis via activation of stress signaling 84,88. Zhang et al reported elevated superoxide 
(O2- ) production and protein carbonyl formation in murine hearts following chronic 
ethanol intake 75.   Enhanced O2- and oxidative stress are well known to promote cardiac 
contractile and intracellular Ca2 + abnormalities as well as interstitial fibrosis 89. It has been 
demonstrated that ethanol may promote free radical generation through direct and indirect 
mechanisms such as aldehyde oxidase and xanthine oxidase-mediated oxidation, leading to 
accumulation of O2- and oxidative stress 90.  The mechanism by which sildenafil 
attenuates ROS generation following alcohol treatment is unclear.  However, recent studies 
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from our laboratory have shown that chronic treatment with the long-acting PDE-5 
inhibitor, tadalafil protected against myocardial ischemia/reperfusion  injury in a type 2 
diabetic mouse via suppression of oxidative stress 91.  In these studies, tadalafil treatment 
attenuated NADPH oxidase activity and expression of NADPH oxidase subunits pRac-1 
and gp91phox and reduced lipid peroxidation in type 2 diabetic hearts. Furthermore, 
tadalafil   treatment preserved the ∆Ψm after ischemia/reoxygenation injury in 
cardiomyocytes isolated from diabetic mice, which is consistent with the effect of 
sildenafil in preservation of ∆Ψm following treatment with ethanol (Figure 11).  In the 
present study, we did not measure NADPH oxidase activity or the expression of the 
enzyme subunits following treatment with ethanol in cardiomyocytes.  There has been very 
limited work done on elucidating the source of oxidative stress in the heart following 
chronic treatment with alcohol.  A recent preliminary report suggested that that chronic 
alcohol intake led to upregulated p47phox (but not p67phox) in the heart, which could be 
one of the potential sources of ROS generation.  Future studies are required to thoroughly 
address the source of radical generation following alcohol toxicity in the heart.  
 
 
 
Conclusions and Future Directions 
 
Our results convincingly show that sildenafil provided significant protective effect 
against alcohol-induced toxicity in adult cardiomyocytes and preserved cardiac function 
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following treatment of mice with alcohol.  There could be potential clinical utility of this 
work for treatment of alcohol-induced cardiomyopathy.  We recognize that abstinence 
from alcohol represents the ultimate treatment to prevent alcohol-induced cardiomyopathy.  
However, in cases where the immediate cessation of alcohol consumption is not possible, 
sildenafil may provide protection against further loss of cardiomyocytes as a result of 
apoptosis with continuing alcohol consumption.  Thus, sildenafil treatment could preserve 
cardiac function until such a time that stopping the cycle of alcohol abuse is possible.  
Given the excellent safety profile of sildenafil in treating erectile dysfunction, we believe 
that the use of sildenafil for the treatment/prevention of alcohol cardiomyopathy could be 
promising.   Today, close to 100 clinical trials with PDE-5 inhibitors have been completed 
or ongoing which focus on the potential cardiovascular benefits (Clinical Trials.gov). 
Clinically, Revatio (sildenafil) is used for treatment of pulmonary arterial hypertension to 
improve exercise ability and slow down worsening changes in the physical condition of 
patients.  Revatio comes in a 20-mg pill that is taken 3 times a day.   Moreover, studies of 
sildenafil on heart failure patients have reported improved exercise capacity, coupled with 
reduced pulmonary vascular resistance and better endothelial function 92. Three clinical 
trials have been initiated to test the utility of PDE5 inhibitors for patients with muscular 
dystrophy. The REVERSEDBMD focuses on the heart and test sildenafil for the treatment 
of Duchenne and Becker dystrophy (Clinicaltrials.gov: NCT01168908).   Several other 
studies also indicated that PDE-5 inhibition with sildenafil has a therapeutic promise for 
stroke, neurodegenerative diseases and potentially other circulatory disorders29.  Our work 
was mainly focused on demonstrating the protective effect of sildenafil against acute 
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alcohol cardiotoxicity at the cellular level and in the intact heart.  Future investigations are 
needed to demonstrate similar efficacy of sildenafil in a chronic model of alcohol 
cardiomyopathy in order to build more compelling case for initiation of clinical trials in 
humans. 
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Figure 20. Proposed Mechanism. PDE-5 Inhibitors enhance the accumulation of cGMP 
and subsequent PKG activity.  In the present study we utilized several strategies, to 
elucidate the role of sildenafil in protection against ethanol, including pharmacologic 
inhibition on PDE-5 with sildenafil, knockdown of PKG with siRNA, overexpression of 
PKG, inhibition of mitoKatp with and 5-HD. The mechanism by which PKG activation 
leads to mitoKatp opening and inhibition of MPTP is not currently known. 
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